Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Medtronic (MDT) Cardiovascular Line Rebounds, Spine Stays Soft
by Zacks Equity Research
Medtronic (MDT) is registering organic growth in the Cardiovascular, Neuroscience and Diabetes segments.
LabCorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.
What's in Store for Canopy Growth (CGC) in Q3 Earnings?
by Zacks Equity Research
New product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to drive Canopy Growth's (CGC) Q3 top line.
Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.
Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust segmental growth and iTero sales are driving Align Technology's (ALGN) Q4 top line.
Align Technology (ALGN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 6.39% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $273.18 in the latest trading session, marking a +0.08% move from the prior day.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Thermo Fisher's (TMO) Q4 earnings surpassed the Zacks Consensus Estimate with strength across the Analytical Instruments segment driving the top line.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.
Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings
by Zacks Equity Research
Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Zacks.com featured highlights include: Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO
by Zacks Equity Research
Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO are included in this blog.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.
LabCorp (LH) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $265.73, moving -0.4% from the previous trading session.
5 Top-Ranked Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings
by Zacks Equity Research
With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.
Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID
by Zacks Equity Research
Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.
LabCorp (LH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $271.57 in the latest trading session, marking a +0.26% move from the prior day.